1350653-24-5

Basic information

• Product Name: 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine
• Synonyms: 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine
• CAS NO: 1350653-24-5
• Molecular Weight: 371.128
• Mol File: 1350653-24-5.mol

Chemical Properties

• Boiling Point: 454.1±45.0 °C(Predicted)
• Density: 1.85±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine(1350653-24-5)
• EPA Substance Registry System: 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine(1350653-24-5)

Safety Data

• Hazardous Substances Data: 1350653-24-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine is used as a building block for the synthesis of complex organic molecules. Its unique structure, which includes a fluorine atom, an iodo atom, and a fluorobenzyl group, allows for the creation of a variety of chemical compounds with different properties and potential applications.
Used in Pharmaceutical Research:
5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine is used as a starting material in the development of new pharmaceuticals. Its distinctive chemical structure may contribute to the discovery of novel drug candidates with potential therapeutic applications.
Used in Chemical Synthesis:
5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine is used as a reagent in the synthesis of other chemical substances. Its presence in the reaction mixture can lead to the formation of new compounds with unique properties, which may be valuable in various industries.
Note: Due to the limited information available on the compound, the above uses are speculative and based on the potential applications of similar compounds in the field of organic chemistry and pharmaceuticals. Further research and development would be necessary to fully understand the capabilities and limitations of 5-fluoro-1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine.

Upstream product

• 1034667-22-5 5-fluoro-1H-pyrazolo[3,4-b]pyridine-3-amine 
• 791644-48-9 2-chloro-5-fluoronicotinonitrile 
• 75302-64-6 2-chloro-5-fluoropyridine-3-carboxamide 
• 82671-02-1 2,6-dichloro-5-fluoro-pyridine-3-carbonitrile 
• 113237-20-0 2,6-dichloro-5-fluoropyridine-3-carboxamide 
• 446-48-0 o-fluorobenzyl bromide 
• 1350653-23-4 5-fluoro-3-iodo-1H-pyrazolo[3,4-b]pyridine 

Downstream Products

• 1350653-26-7 5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile 
• 1350653-25-6 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-nitropyrimidine-4,6-diamine 
• 1350653-29-0 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazenyl]pyrimidine-4,6-diamine 
• 1350653-30-3 2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine 
• 1350653-20-1 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yl}carbamate 
• 1350653-21-2 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate 
• 1350653-22-3 methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}(2,2,2-trifluoroethyl)carbamate 

Relevant articles and documents

Pyrazolopyridine compound and use thereof

The present invention relates to a pyrazolopyridine compound and use thereof, and further relates to a pharmaceutical composition comprising the pyrazolopyridine compound. The pyrazolopyridine compound or the pharmaceutical composition can be used as a so

BICYCLIC AZA HETEROCYCLES, AND USE THEREOF

The present application relates to novel bicyclic azaheterocycles, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF

The present application relates to novel substituted fused pyrimidines and triazines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

RING-FUSED PYRIMIDINES AND TRIAZINES AND USE THEREOF FOR THE TREATMENT AND/OR PROPHYLAXIS OF CARDIOVASCULAR DISEASES

The present application relates to novel fused pyrimidines and triazines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES

The present application relates to novel fused 4-aminopyrimidines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for th

USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES

The present invention relates to the novel use of stimulators and activators of soluble guanylate cyclase for the treatment of sickle cell anemia and for the preservation of blood substitutes. The present invention furthermore relates to the use of stimulators and activators of soluble guanylate cyclase in combination with PDE5 inhibitors for the treatment of sickle cell anemia and for the preservation of blood substitutes.

Substituted annellated pyrimidines and use thereof

The present application relates to novel substituted annellated pyrimidines, methods for production thereof, use thereof alone or in combinations for treating and/or preventing diseases and use thereof for the production of medicinal products for treating

Substituted 5-fluoro-1H-pyrazolopyridines and their use

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.